Haplotype-Based Banking of Human Pluripotent Stem Cells for Transplantation: Potential and Limitations

Zimmermann, Anna; Preynat‐Seauve, Olivier; Tiercy, Jean‐Marie; Krause, Karl‐Heinz; Villard, Jean

doi:10.1089/scd.2012.0088

Cited by 59 publications

(44 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and the question of establishing a hiPS bank with well defined genetic characteristics is on debate. These hiPS would cover a large panel of population, so each individual would be matched with a specific hiPS cell line [23,24]. Such cell lines could also be tested in presence of ISD to validate the absence of interference on cell differentiation steps as well as their impact on maturation and cell functionality.…”

Section: Discussionmentioning

confidence: 99%

The Role of Immunosuppression in the Transplantation of Allogenic Neural Precursors Derived from Human Pluripotent Stem Cells for Parkinson’s Disease

Rham¹,

Tieng²,

Tournier³

et al. 2013

J Stem Cell Res Ther

View full text Add to dashboard Cite

Objective: Neural progenitor cells (NPC) derived from human embryonic stem cells have the potential to differentiate into mature neurons after transplantation in the brain, opening the possibility of regenerative cell therapy for neurodegenerative disorders like Parkinson's disease. For such therapy, the source of NPC is genetically unrelated to the patient, leading to potential rejection of the transplanted cells by the host's immune response. Rejection can be prevented by the use of immunosuppressive drugs (ISD). Previous works have suggested that cyclosporine and dexamethasone used in classical immunosuppressive regimen could prevent the terminal differentiation of NPC into mature neurons depending on culture conditions. Methods:We have investigated in vitro the role of other ISD, Intra venous Immunoglobulins (IvIG), mycophenolate mofetil and tacrolimus. We have tested the immunosuppressive activity of tacrolimus and cyclosporine on the effector of natural killer (NK) and CD8 + T-cells and performed a microarray to analyse the difference between the two drugs for the neuron differentiation. Finally, human transplanted neuroprecursor cell survival has been analyzed in rats treated with tacrolimus or cyclosporine and anti-inflammatory treatments.Results: IvIG and mycophenolate mofetil interfere with the development of NPC into mature neurons, but tacrolimus do not inhibit the maturation process of NPC. Microarray experiments demonstrate significant differences between cyclosporine and tacrolimus gene expression during NPC maturation into mature neurons. Tacrolimus like cyclosporine is able to inhibit the CD8 + T-cells activation against neural progenitors, but both are unable to block NK cells activity. NK cells could be potential harmful weapons to reject NPC and mature neurons. In rats treated with both immunosuppressive (tacrolimus or cyclosporine) and anti-inflammatory treatments, engrafted human neuroprecursors cell survival is good and the microglial density is low. Conclusion:These data suggest in vivo that both tacrolimus and cyclosporine, with an anti-inflammatory treatment like prednisolone, promote graft survival and minimise the host microglial response.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Immunosuppression in the Transplantation of Allogenic Neural Precursors Derived from Human Pluripotent Stem Cells for Parkinson’s Disease

Rham¹,

Tieng²,

Tournier³

et al. 2013

J Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…Finally, there is concern that autologous iPSCs may be immunogenic, though this issue has been somewhat resolved by the work of Araki and colleagues, who showed that this may only be true for pluripotent iPSCs, and not for their terminally differentiated progeny (Zhao et al, 2011;Araki et al, 2013;Guha et al, 2013). An alternative approach to the use of autologous iPSCs is the development of banks of undifferentiated cells that could be differentiated into the desired cell type and transplanted to human leukocyte antigen-matched recipients (Zimmermann et al, 2012) With the unknown long-term effects coupled with the potential forced expression of known proto-oncogene genes, caution must be exercised before iPSC-based treatment can be extrapolated into the clinical environment. Furthermore, the cost of truly allogenic iPSC therapy, using current technology, would be too high to produce these treatments on the large scale needed to meet the massive demands of a disease such as macular degeneration.…”

Section: Using Ipscsmentioning

confidence: 99%

Stem cells in retinal regeneration: past, present and future

et al. 2013

View full text Add to dashboard Cite

SummaryStem cell therapy for retinal disease is under way, and several clinical trials are currently recruiting. These trials use human embryonic, foetal and umbilical cord tissue-derived stem cells and bone marrow-derived stem cells to treat visual disorders such as age-related macular degeneration, Stargardt's disease and retinitis pigmentosa. Over a decade of analysing the developmental cues involved in retinal generation and stem cell biology, coupled with extensive surgical research, have yielded differing cellular approaches to tackle these retinopathies. Here, we review these various stem cell-based approaches for treating retinal diseases and discuss future directions and challenges for the field.

show abstract

“…There has been a recent trend towards the development of HLA haplotype banks of clinical grade PSCs that address the needs of the majority of the population within a geographical location, while minimizing risk of allograft rejections (Gourraud et al, 2012;Nakatsuji et al, 2008;Taylor et al, 2012;Zimmermann et al, 2012). There are many commercially available assays for low-resolution typing that are generally faster and cheaper or for high-resolution typing with an extended set of molecular assays to characterize the alleles in more detail.…”

Section: C) Hla Analysismentioning

confidence: 99%

“…This includes passaging formats, split schedule, and determining how culturing vessels will be labeled and maintained (see Section 4.3). These et al, 2008;Taylor et al, 2012;Zimmermann et al, 2012) but further guidelines may emerge as more cells enter the clinical space. Specific requirements for such testing to enable immunological matching will be subject to regional variations in haplotype incidence and may also need to include analysis for other types of polymorphic cell surface molecules.…”

Section: Handling and Maintenancementioning

confidence: 99%

Good Cell Culture Practice for stem cells and stem-cell-derived models

Pamies

2017

Toxicology Letters

View full text Add to dashboard Cite

SummaryThe first guidance on Good Cell Culture Practice (GCCP) dates back to 2005. This document expands this to include aspects of quality assurance for in vitro cell culture focusing on the increasingly diverse cell types and culture formats used in research, product development, testing and manufacture of biotechnology products and cell-based medicines. It provides a set of basic principles of best practice that can be used in training new personnel, reviewing and improving local procedures, and helping to assure standard practices and conditions for the comparison of data between laboratories and experimentation performed at different times. This includes recommendations for the documentation and reporting of culture conditions. It is intended as guidance to facilitate the generation of reliable data from cell culture systems, and is not intended to conflict with local or higher level legislation or regulatory requirements. It may not be possible to meet all recommendations in this guidance for practical, legal or other reasons. However, when it is necessary to divert from the principles of GCCP, the risk of decreasing the quality of work and the safety of laboratory staff should be addressed and any conclusions or alternative approaches justified. This workshop report is considered a first step toward a revised GCCP 2.0.

show abstract

Haplotype-Based Banking of Human Pluripotent Stem Cells for Transplantation: Potential and Limitations

Cited by 59 publications

References 60 publications

The Role of Immunosuppression in the Transplantation of Allogenic Neural Precursors Derived from Human Pluripotent Stem Cells for Parkinson’s Disease

The Role of Immunosuppression in the Transplantation of Allogenic Neural Precursors Derived from Human Pluripotent Stem Cells for Parkinson’s Disease

Stem cells in retinal regeneration: past, present and future

Good Cell Culture Practice for stem cells and stem-cell-derived models

Contact Info

Product

Resources

About